# A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

> **NCT05319353** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 80 (estimated)

## Conditions studied

- Cytomegalovirus (CMV)

## Interventions

- **DRUG:** Maribavir

## Key facts

- **NCT ID:** NCT05319353
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2027-01-18
- **Final completion:** 2027-01-18
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319353, "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05319353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*